click contribut analyst contact
view biotech sector driver
come
recent turnaround expect maintain
momentum biotech sector buoy
continu activ improv sentiment follow
recent string favor clinic commerci regulatori
catalyst howev believ thing could level spring
drug price polici rhetor pick bd activ potenti
highest-qu growth expens small-cap
provid consider upsid opportun among select name
binari favorit name includ gmab
ovid apto moln clin ln
biotech team host confer call et
wed dec pleas contact salesperson dial-in
differ month make mani month
biotech trade forgotten sector slow near-
halt posit clinic newsflow seem hard come drug price
worri stimul rhetor presidenti primari
campaign legisl leader put forth pharmaceut cost
contain initi made mani view space unown
sentiment look like hit rock bottom seem like
blink eye entir group revers cours even jade
investor recogn valuat pendulum like swung far
large-cap multipl bottom summer spur
primarili seri surpris posit data catalyst among small-
cap revit growth opportun
previously-stagn larger cap aducanumab
otezla resurg consider premium mdco
bold arql thor ibb xbi roar date
vs solid commerci execut increas
polit gridlock around drug price smid/mid-cap product adopt
smaller co hold launch improv leverag
potenti scenario certainli didnt hurt group show
sign slow see room run especi given
sector remain underown mani generalist like return
space given demonstr alpha
 elect chronolog order like
central theme despit uneven throughout cours
forc believ would stimul meaning pickup
acquisit coalesc gener new high biopharma acquisit
record number announc public compani deal full
report backpag
price prior trade day market close estimate unless otherwis note
valu usd unless otherwis note
requir non-u analyst conflict disclosur see page
dont think trend finish least near term first part
mani potenti buyer remain capit remain cheap larger compani need
growth pipelin balanc sheet stabil manag team deploy
valuat among possibl acquisit target escal substanti
potenti limit acquir return invest market increasingli
reward use cash busi develop bd averag increas share price
first day deal vs decreas last year place greater weight
growth pipelin promis roi cash reserv expect bd player remain
base experi expect preval therapeut area play
includ gene therapi neurolog inflamm oncolog overal believ
sustain activ space drive addit stock momentum across
qualiti smid-cap view potenti target sweet spot market cap window
well large-cap revit narr better visibl toward diversifi
polit wind pick spring potenti stall momentum
group especi begin slow analysi confirm biotech group
extrem sensit polit nois clinton tweet unravel sector
remark invers correl stock price warren stand
democrat primari poll focu drug price candid legisl wane
least time impeach taken center stage could well
chang rhetor could pick particularli warren sander emerg
frontrunn primari ultim work earlier year suggest
believ potenti impact realist concept medicar polici
chang chang part catastroph coverag part would modest
large/mid-cap biotech revenu even unlik worst-cas scenario group
democrat sweep white hous hous congress elect
likelihood policymak abl come togeth uniform agenda
substanti compress drug reimburs seem slim exemplifi current
diverg view even within parti lead stalem delay nonetheless
stock reflect increas optim around futur market posit price power
mani development product despit competit environ could make valuat
fragil even increment unfavor polici develop addit
time nois around drug price escal could wane mani compani
hunt would replenish pipelin uncertainti around monetari polici ftc
stringenc reimburs polici new administr potenti dissuad bd
activ hint recess could spark concern capit window unprofit
smaller-cap biotech might becom constrain overal would ride biotech
wave spring expect thing level thereaft though still
favor view toward certain mid-cap compani given recent run-up select
under-valued larg cap under-the-radar small cap might make interest
invest opportun
regulatori polici look outsiz impact space fail phase
year ago use mean go back draw board there even
hint activ diseas there unmet need compani investor alik
push file hope approv see realist
hope realli remain seen well sure learn much come
year though true recent histori amen srpt exondi
approv open-label ph ii rapid vrtx trikafta gbt oxbryta approv month
ahead pdufa high unmet need condit also moment surprisingli
greater stringenc srpt initi golodirsen exampl especi come
safeti far largest test regulatori flexibl fda handl biib
aducanumab also number updat potenti approv late-
icpt oca nash path forward srpt muscular dystrophi gene therapi
itci lumateperon schizophrenia instrument gaug agenc
balanc mix data surrog endpoint manufactur uncertainti signific
unmet need bar sure impact investor percept market valuat
compani relat therapeut vertic whole sector come year
ad complex decis occur newly-appoint fda leader
limit on-the-record regulatori view restructur offic new drug --
backdrop elect year could nave think polit forc wont
influenc
drug launch potenti shape biopharma sector year come
perhap salient question around drug launch prospect whether potenti
differenti new product gain traction alreadi well-establish agent
class/diseas harbor signific physician experi formulari entrench
launch abbv rinvoq ra bmi ozanimod ms lun eptinezumab abbv
ubrogep migrain roche/ptct risdiplam sma bcrx berotralstat
elucid much sale expans market therapeut area bear
critic advantag new drug need nowaday conveni
efficaci safeti gain share well also learn launch
readili dramat therapeut innov past year translat
revenu gener someth sure shape sentiment valuat development-
stage biotech well futur sever import question reson
well nash space repres public biotech market cap realist
penetr icpt oca larg novel neuro gwph epidiolex nbix ingrezza
sage zulresso biib spinraza acad nuplazid hematolog bmy/xlrn reblozyl
gbt voxelotor spaces/drug rapid plateau will payer
stretch budget cancer combo one-tim gene therapi luxturna
zolgensma go like prospect risdiplam oca ingrezza vrtx
trikafta given signific differenti and/or substanti unmet need
report examin depth key theme like influenc sector year
next decad sentiment drug pricing/policy/elect regulatori landscap
innov competit earn growth patent cliff financ environ
human capit factor similar last year import except
elect overlay drug price polici potenti impact evolv
sentiment bottom summer sentiment look optimist
larg predic bullish around expect continu
major favor sector driver least earlier part year
drug polici price elect year howev remain import headwind
though believ impact realistically-implement polici propos like
modest valuat optimist drug price histor sector
sensit polit nois increas rhetor around cost contain initi
potenti campaign heat mid-year could cool recent ralli
remain posit overal regulatori landscap given benefit
collabor agenc multitud recent earli approv though bit
temper time last year given high hope alreadi regulatori
flexibl across board unknown impact structur leadership chang
fda
see innov remain robust continu progress gene therapi
antibodi technolog unmet need neuropsych area like alzheim
huntington return center stage inflammatori diseas grow albeit
innov come intensifi competit space anti-vegf
ophthalmolog oral jak inhibitor inflammatori diseas sma like play
view increasingli import investor assess increasingli dynam treatment
landscap market share discount implic
earn growth prospect mid/large-cap biotech look improv strong
improv growth expect among sever larger-cap name
solid execut continu mid-cap view
even challeng could gener growth bolt-on pipelin
also keep eye financ environ remain strong could
turn price concern re-emerg space overal signal
mani larger-cap small molecul drug develop compani
still face patent cliff could place ceil valuat year
tecfidera inci jakafi follow continu evolut
amgn base busi follow loss small-molecul sensipar biolog neulasta
off-set success defens enbrel ad fourth decad brand sale
product set emerg new gener focal point kuvan slate stage
generic howev anticip signific attent paid
celg merger preced celg/bmi newco out-performance might make
patent-cliff induc mega-merg palat biopharma execut
manag team among larger biotech compani becom re-establish
provid benefit clearer articul strategi bd plan though
mani compani remain constrain respect human capit experi
name like
large-cap side
abraham top pick pt continu trade discount vs slower-
grow pharma despit expect good long-term hiv sustain
underr pipeline/lif cycl prospect stabil ep limit clinic competit
price patent risk new manag helm strong balanc sheet
work expect compani proactiv bolt compani asset
bolster growth narr catalyz multipl expans
gmab mackay outperform pt one prefer name
compani aim capit histori success intern advanc
novel pipelin vs partner earli util steadili climb non-dilut royalti
stream darzalex continu grow multipl myeloma see
continu upsid darzalex beats/rais howev anticip increas focu
appreci gmab novel outside-the-box approach antibodi engin
focu tv pipelin agent drive investor
enthusiasm longer term like gmab profit platform ingenu
could make compani attract partner even takeout target larger
biopharma compani focus expand pipelin
mid-cap side
though could continu up down along road
ultim confid srpt abraham outperform pt key value-driv
muscular dystrophi gene therapi program confer meaning function benefit
find path approv abl manufactur believ clariti
front come year would drive share consider higher
given market opportun believ compani current market cap
prove highli attract long-term entri point
mackay outperform pt non-consensu pick see potenti
trial read posit benefit overal surviv
parallel recent data anticip cabonivo growth lucr
rcc back data mo advantag achiev could inflect cabo slow
commerci trajectori lead anoth leg commerci growth excit
stock overhang preclud name enjoy
investor enthusiasm seen broader biotech market gain
date vs nbi gain howev see downsid rel limit
data given exel sustain profit rel low price-to-earnings multipl
line pharma compani
continu revenu strength nuplazid pdp streak solid data hand
toward meaning expans pimavanserin drp indic view
acad renza outperform pt neuropsychiatr franchis potenti
pimavanserin broader clinic util high-qual under-appreci
regulatori path drp crystal believ like approv nuplazid
place pdp deepen commerci see critic year continu
build clinic foundat ultim support collect multibillion dollar peak
reactiv pipelin oncolog led establish path role
md treatment paradigm among focus popul mutant patient
meaning catalyst setup year ph iii march toward readout
sever adjac program continu progress well-posit
view meet unmet need mutant mds/aml patient ultim
success see peak sale potenti exceed world-wide
mackay outperform pt enter pivot year prepar submit
lead agent oraxol oral paclitaxel encequidar ope fda approv treatment
metastat breast cancer pathway see oraxol data suffici
approv anticip increas posit kol commentari atnx under-the-
radar dataset gain widespread kol attent longer term anticip oraxol
see high commerci demand breast cancer patients/yr elig singl agent
paclitaxel prior broaden indic gain broader platform
recognit atnx orascoveri platform beyond paclitaxel
sea small-cap stock appreci ovid abraham outperform specul risk
pt still look us signific disconnect qualiti
programs/manag valuat novel neuro program alway
consider risk potenti angelman data underappreci
asset transform fx result possibl support activ data
epilepsi trial increasingli promis agent soticlestat throughout see
favor asymmetr reward/risk share busi data year
believ apto renza outperform specul risk pt uniqu under-the-
radar target oncolog pipelin potenti garner increas attent year
clinic data emerg ph dose escal lead asset multi-clust
inhibitor program advanc aml given apto care
ambiti clinic plan back increas valid next-gener target
agent btki apto initi path toward attract clinic commerci
prospect view peak potenti across target aml b-cell
benefit develop drug candid overcom limit convent
antibodi manufactur fraction cost believ market
undervalu pipelin potenti see attract opportun
enter clinic whilst first multi-darpin vegfx hgf
show impress data orr heavili pretreat multipl myeloma
compani look partner abicipar out-licens allergan expect
approv fda/ema model mileston payment moln
upon launch exclud potenti abicipar mileston cash runway
follow deal decemb up-front payment
addit clin ln weston top pick gbp pt strong posit within
structur grow pharma servic nich believ market fail price
upsid proleukin aldesleukin new indic drug
studi trial includ alongsid iovanc lifileucel melanoma cervic
cancer al trial provid immedi revenu success
could ultim worth clinigen exist market cap recent
acquisit synthorx whose lead candid valid resurg
interest area
biotech catapult next decad face year there like lot
happen lot stake end chang grow posit
even better help guid analysi headlin progress biotech
sector look forward continu work year great holiday season
prosper
-- brian kennen greg biotech
tabl content click navig
review outlook
summari view
biotech coverag univers
top idea
theme drug price polici elect
theme earn growth
learn think
mid-cap consist outperform broader market large- small-cap biotech make
recent posit pipelin develop solid print cool drug price
concern like contribut recent appreci low
mid-cap continu outperform help increas enthusiasm posit data readout
small-cap trade mostli line larg cap biotech
price
outlook neutral posit new biotech leadership visibl revenu growth
sever biotech off-set increas competit threat less permiss regulatori environ
bullish head outlook earn growth competit improv
along investor sentiment though note potenti increas headwind approach
elect later year
overal compar came key themat area space stay
improv
bearishneutralneutralslightli bullishdrug price polici electionslightli bearishneutralslightli bearishslightli bearishslightli bearishm aslightli bullishslightli bearishveri bullishveri bullishveri bullishregulatori landscapeveri bullishveri bullishveri bullishslightli bullishslightli bullishinnovationveri bullishveri bullishveri bullishveri bullishveri bullishcompetitionslightli bearishslightli bearishslightli bearishveri bearishslightli bearishearn growthslightli bearishveri bearishveri bearishslightli bearishslightli bullishfinanc environmentslightli bullishveri bullishneutralneutralneutralpat cliffsslightli bullishneutralneutralneutralneutralhuman capit -- neutralslightli bullishslightli bullishslightli bullishneutralneutralslightli bullish headwindsneutralslightli bearishslightli bearishslightli bearishneutr tailwindsslighli bullishbullishslightli bullishslightli bullishslighli bullish biotech outlook ride momentum polit wind pick
summari view key sector headwind tailwind
innov -- innov within biotech core driver sector remain
high level particularli current environ regulatori facilit
expect continu advanc scienc around -emerg area
includ gene manipul neurolog target oncolog gener
steadi stream high-potenti pipelin program enthusiasm group
assum manufactur deliveri reimburs keep pace
sentiment -- overal investor sentiment optimist larg
predic prospect could continu renew generalist
enthusiasm potenti money flow space still drug price concern
remain overhang sector sentiment stock action could suscept
slowdown deal increas polici rhetor potenti send
generalist investor back sidelin wait elect
capit -- re-establish senior manag team mani larger
biotech enabl firmer articul busi strategi
proactiv capit alloc effort well receiv
coupl lengthi tenur mid/smid-cap compani improv
percept stabil biotech space though sever team
remain incomplete/untest scarciti valu oper personnel
cutting-edg scientif area could repres underappreci risk
 -- balanc sheet strong money cheap pipelin thin better
market recept see stage set continu deal momentum
record pace -- continu drive near-term upsid group --
though believ could wane progress target digest
potenti election-rel uncertainti
earn growth -- come year believ import
sector build upon progress includ solid commerci
execut bd help revit large-cap stori
continu expand
multipl closer larger pharma despit increas expect matur
franchis still see large-cap valuat overli discount
dynam long-term growth prospect look promis mid-cap biotech
regulatori landscap -- believ overal regulatori trend continu look
favor given appar continu push fda new treatment
modal innov chang fda appear gear toward
streamlin drug assess approv process increasingli
polar polit environ combin appear somewhat
unfavor trend approv volum temper bullish expect
regulatori landscap continu net tailwind sector
drug price polici -- initi combat escal drug price
increasingli popular across parti expect uptick rhetor
elect rekindl investor concern cool sector momentum
potenti exacerb ascend
presidenti candid erod poll number presid trump though
continu believ polit structur challeng ultim make
implement meaning polici chang unlik
competit -- expect competit biotech remain brisk though
note sever competit situat larg play cgrp
lead revis out-year expect look ahead
begin see competit dynam play area like anti-
vegf oral jak inflammatori diseas sma though slightli
less bearish view go vs still believ competit
import headwind watch close
financ environ -- improv post-ipo perform stabl follow-
market maintain healthi access capit biotech compani
see major financ hurdl public privat sector
least first part howev potenti neg data new
recess fear context
early-stag compani emerg
increasingli high capit need potenti
diminish financ
patent cliff -- compani reason well stave patent
cliff concern litig victori pipelin enhanc busi
develop administr polici remain favor drugmak
 lawmak slow implement actual chang favor uspto polici
continu help brand drugmak defend ip flip side sever
import life cycl strategi among mid/large-cap compani need
elucid eros biosimilar becom tangibl
could headlin risk politician increasingli weigh drug-rel ip
year biotech sell-sid
yea biotech sell-sid experi
md brown medic school ba
previous cover biotechnolog
biolog brown univers
md albert einstein colleg
sector credit suiss
pursu special medic train
bs molecular biophys
biochemistri yale univers
phd biochemistri ucla
ba colorado colleg
manag consult booz co
interest scienc medicin
new associ licens new year
new associ licens new year
virolog
phd cell biolog
phd scienc
bs/ba doubl degre neurosci
prior experi biotech vc
medic univers
econom univers pittsburgh
look forward work upon
prior tenure-track associ professor
univers virginia
conduct biomed research
support research
inflamm acut kidney injuri
join abraham biotech equiti
research team
prior buy-sid experi ny hedg
fund focus therapeut
join abraham biotech equiti
research team
immunolog
allergi asthma
mbb india institut medic
year biopharma competit
intellig healthcar consult
experi sagient informa
ba econom uc san diego
join mackay biotech equiti
research team
clinic biomed research
experi aiim john hopkin
phd biolog scienc special
biophys carnegi mellon
ms biochemistri oncolog
concentr univers nebraska
prior experi alvarez marsal
bs biolog zhejiang univers
biotechnolog equiti research mizuho
join mackay biotech equiti research
team
prior experi healthcar invest
join mackay biotech equiti
research team
phd biolog
look forward work
phd ucl molecular biolog
bsc liverpool univers
year experi roch year
biomark clinic develop
year busi develop
join
year industri experi
med-tech genom
mchem univers oxford
price
stock coverag across three analyst team span cap size numer therapeut area
year cumul sell-sid research experi across franchis
graduate-level profession degre industri expertis across scientif research drug develop clinic medicin payer price
reimburs commerci strategi market analyt busi develop financ intellectu properti regulatori
pharmaci distribut suppli chain
compon rbc comprehens healthcar research cover key core subsector
top idea
abraham top pick price target continu trade discount vs slower-grow
pharma despit expect good long-term hiv sustain underr pipeline/lif cycl prospect
stabil ep limit clinic competit price patent risk new manag helm
strong balanc sheet work expect compani proactiv bolt compani asset
bolster growth narr catalyz multipl expans
gmab mackay outperform price target gmab one prefer name compani aim
capit histori success intern advanc novel pipelin vs partner earli util
steadili climb non-dilut royalti stream darzalex continu grow multipl myeloma
see continu upsid darzalex beats/rais howev anticip increas focu appreci
gmab novel outside-the-box approach antibodi engin focu
tv pipelin agent drive investor enthusiasm longer term like gmab profit
platform ingenu could make compani attract partner even takeout target larger biopharma
compani focus expand pipelin
abraham outperform price target though could continu up
down along road ultim confid srpt key value-driv muscular dystrophi gene therapi
program confer meaning function benefit find path approv abl manufactur
believ clariti front come year would drive share consider higher given
market opportun believ compani current market cap prove highli attract
top idea continu
mackay outperform price target non-consensu pick see potenti checkmate-
trial read posit benefit overal surviv parallel recent data anticip cabonivo
growth lucr rcc back data mo advantag achiev could inflect cabo slow
commerci trajectori lead anoth leg commerci growth excit stock overhang checkmate-
preclud name enjoy investor enthusiasm seen broader biotech market gain
date vs nbi gain howev see downsid rel limit data given exel
sustain profit rel low price-to-earnings multipl in-lin pharma compani
renza outperform price target continu revenu strength nuplazid pdp streak solid
data hand toward meaning expans pimavanserin drp indic view acad neuropsychiatr
franchis potenti pimavanserin broader clinic util high-qual under-appreci regulatori
path drp crystal believ like approv nuplazid place pdp deepen commerci see
critic year continu build clinic foundat ultim support collect multibillion dollar
ovid abraham outperform spec risk price target sea recent small-cap stock appreci ovid still look
us signific disconnect qualiti programs/manag valuat novel neuro
program alway consider risk potenti angelman data underappreci asset
transform fx result possibl support activ data epilepsi trial increasingli promis
agent soticlestat throughout see favor asymmetr reward/risk share busi data year
moln karamanoli top pick spec risk chf price target darpin technolog offer benefit develop drug
candid overcom limit convent antibodi manufactur fraction cost
believ market undervalu pipelin potenti see attract opportun
enter clinic whilst first multi-darpin vegfx hgf show impress data orr heavili
pretreat multipl myeloma compani look partner abicipar out-licens allergan expect
approv fda/ema model mileston payment moln upon launch exclud potenti
abicipar mileston cash runway follow deal decemb up-front
payment preclin asset
top idea continu
mackay outperform price target enter pivot year prepar submit lead
agent oraxol oral paclitaxel encequidar ope fda approv treatment metastat breast cancer
pathway see oraxol data suffici approv anticip increas posit kol
commentari atnx under-the-radar dataset gain widespread kol attent longer term anticip
oraxol see high commerci demand breast cancer patients/yr elig singl agent paclitaxel
prior broaden indic gain broader platform recognit
pipelin oncolog led establish path role md treatment paradigm among
focus popul mutant patient meaning catalyst setup year ph iii march
toward readout sever adjac program continu progress well-posit
view meet unmet need mutant mds/aml patient ultim success see peak
clin ln weston top pick price target addit strong posit within structur grow
pharma servic nich believ market fail price upsid proleukin aldesleukin
new indic drug studi trial includ alongsid iovanc lifileucel melanoma
cervic cancer al trial provid immedi revenu success could
ultim worth clinigen exist market cap recent acquisit synthorx whose lead
candid valid resurg interest area
apto renza outperform spec risk price target believ apto uniqu under-the-radar target
oncolog pipelin potenti garner increas attent year clinic data emerg ph
dose escal lead asset multi-clust inhibitor program advanc aml given
apto care ambiti clinic plan back increas valid next-gener target agent
btki apto initi path toward attract clinic commerci prospect view
peak potenti across target aml b-cell malign popul
evalu top theme look
investor survey indic continu optim go
investor maintain increas posit expect
biotech sector larg outperform page
investor view sector sentiment innov key posit
driver page agre innov
character bullish influenc believ
prospect favor regulatori environ
therapeut area emerg drive sector perform given
clear increas investor enthusiasm toward space
see generalist enthusiasm group rise past
month base survey result continu grow given
sector move likelihood continu
flow rel even middl
sandwich declin page think
 activ necessari maintain sector strength
polit pressur drug price build democrat
remain key concern cite investor
go page believ money re-ent sector
larg predic continu believ
prospect suffici sustain ralli actual
 occur could requisit generalist maintain
optim toward sector
drug price polici far top concern survey investor
re-emerg polit rhetor around expect like
mid-year elect approach would like quickli cool
sentiment money flow group
beyond drug price concern competit primari concern
among investor though lesser extent investor
monitor emerg new therapeut class impact
take overal investor sentiment optimist larg predic prospect could continu renew
generalist enthusiasm potenti money flow space still drug price concern remain overhang sector sentiment
stock action could suscept slowdown deal increas polici rhetor potenti send generalist investor back
sidelin wait elect
survey investor gaug sentiment go
respond mix specialists/generalist long-only/long-short
investor mostli see sector under-valued head
respond think valuat high
believ reflect mix sentiment space current lean posit sector
specialist cautiou
smaller portion survey
investor view space
under-valued compar
last check octob
valuedundervaluedcurr investor view biotech valuedundervaluedcurr investor view biotech valuationsgeneralistsspecialist biotech outlook ride momentum polit wind pick
expect sector vs broader market slightli posit major
investor expect biotech outperform
generalist heavili expect sector outperform broader market vs specialist
evenli split expect
investor optimist
sector rel perform
octob driven
primarili shift generalist
 in-lin expect rel biotech in-lin expect rel biotech performancegeneralistsspecialist biotech outlook ride momentum polit wind pick
major investor plan maintain posit
investor plan decreas exposur sector generalist wait-and-se mode
even recent ralli
investor plan increas
exposur compar
survey octob
posit posit biotech outlook ride momentum polit wind pick
among large-cap name investor mostli favor top expect
generalist lean favor specialist favor howev generalist expect good year
least prefer large-cap among investor survey
investor look toward activ drive perform drug price
concern continu worsen
investor seem optimist prospect sentiment drive sector growth
drug price polici remain primari concern despit lack progress legisl
competit next biggest concern investor biosimilar gener innov therapeut
investor cite sentiment
one biggest tailwind
reflect shift
percept generalist
sentiment sector
concurr fewer
approv lower
approv rate
investor see regulatori
landscap less favor
head
environmentearn growth valuationhuman capitalpat cliffsregulatori landscapecompetitiondrug price policyinvestor select biggest posit neg driversheadwind neg group tailwind posit avgsbiggest tailwind driver biggest headwind -driver biotech outlook ride momentum polit wind pick
fund flow primarili neg driven larg outflow gradual declin
latter month year
generalist money movement measur vs prior year larg monthli swing
underscor stabl string month middl year
drug price polici elect
recent legisl gridlock administr inact highlight low
likelihood split white house/congress legisl
execut plan highli impact drug price ultim goe
even unlik case democrat sweep white hous
senat hous elect highli differ view within
net price reach steadi state expect
revenu growth price power come
novel strategi value-bas initi could continu improv
reimburs paradigm new market entrant offer
insul market orphan drug certain oncolog class stay
protect continu see premium price set new
product though competit market remain expos
sentiment
particularli among generalist strongli tie expect trump
re-elect democrat gain poll money flow
space could diminish
combat rise drug price includ radic method like
reimport patent revoc increasingli bipartisan
agenda includ republican even moder
democrat add risk escal rhetor elect
rekindl price worri cool sector momentum
biotech tape highli invers correl elizabeth
warren stand democrat primari poll
resurg left-lean democrat primari could rapid
competit market like particularli expos payer
target therapeut area sever option cost contain
state drug price initi continu ramp
take initi combat escal drug price increasingli popular across parti expect uptick rhetor elect
rekindl investor concern cool sector momentum potenti exacerb ascend left-lean democrat presidenti candid
erod poll number presid trump though continu believ polit structur challeng ultim make implement
elect dynam impact healthcar sector biopharma specif
starter drug price concern larg dissip enter final month lead
next elect
senat action grassley/wyden plan pdra reform medicar curb drug cost wont come earli next
year best though plan remain least impact current float dc
pelosi hous bill consid doa senat especi democrat caucu eke left-lean
concess plan decemb -- includ up number drug subject negoti
addit protect employer-sponsor beneficiari drug price spike
presid highli anticip execut order medicar issu earli octob includ anyth
saw major implement chang drug price healthcar polici
leav us
focu shift first foremost presidenti elect respond survey overwhelmingli expect
anoth year trump white hous mean expect low hotly-deb democrat
propos thrown primari season make to/through white hous
still sentiment sector strongli associ trump re-elect prospect could trigger investor
jitter poll well futur democrat candid
beyond republican look like retain control senat impli probabl bloomberg peg
republican chanc control upper chamber
hous seem pois remain democrat control bloomberg data predict likelihood
democrat retain gavel lower hous
chanc democrat control hous senat white hous impli
likelihood democrat sweep would facilit potenti smoother path drug price polici
implement mean sector insul fear next year left-lean
overal field stand healthcar polici poll
drug price reform
medicar negoti
directli drug price limit
launch price special
therapeut limit
increas across drug
medicar directli
negoti
price higher
great britain requir
rebat gener price
increas outpac
inflat allow import
drug form countri
medicar directli
drug import form
negoti cost drug
arthriti among
would priorit tax
gross drug sale
fail negoti
increas
quarter government
could also revok patent
compani refus compli
ban pay delay
innov enabl hh
littl competit
price practic disclosur
model price
support improv
plan
innov enhanc
speed market select
macro requir hospit
disclos negoti rate
patient forc
insur compani
innov acceler
review approv
macro increas valu
tax credit expand
bill out-of-network
biopharma ad spend
support innov
medicaid
protect
regulatori review
invest drug
price cap oop
spend senior
generalist expect sector vs broader market mirror expect around
elect could slow generalist flow trump re-elect chanc look less like
generalist poll overwhelmingli expect trump
re-elect mirror expect
biotech out-performance vs
generalist expect democrat victori
white hous biotech under-perform
poll support anecdot feedback
meet generalist investor suggest
increas consider biotech portfolio
result suggest sector could see
turbul democrat get closer nomin
candid direct poll vs presid trump
conduct democrat candid poll favor
vs presid
long specialist group give
presid less chanc re-elect
aggreg specialist expect anoth four
year trump white hous expect
sector outperform market potenti
reflect slightli higher overal expect
democrat oval offic
expect vs in-lin specialistlong-shortgeneralistlong-shortspecialisttotaldo expect donald trump warren- sign biotech tape highli invers correl elizabeth warren stand poll
resurg left-lean democrat could rapid neg effect biotech
warren candidaci first half
year though sentiment
began move invers
poll establish
contend
democrat field poll
relationship becam
evid octob
start backtrack
correspond drop
poll number
swing nbi
popular poll
chang stanc appear
strong invers correl
biotech indic
warren hit hard
wsh sq park ralli
eo medicar
bottom
perform index feb pollingwarren poll vs nbi performancewarren nation pollingnbi averag list price increas prior year major biotech product continu declin
slower rate expect reach steadi state start
note analysi includ product bmy/celg relev competit
list price increas slow increas discount net drug price decreas
follow slight uptick correl growth sale volum thu
measur price increas drug price decreas q-o-q offset growth sale
volum therefor signific chang overal sale observ
expect continu pressur commerci payer govern polici keep drug price major
growth could lower compani revenu growth sale volum reach threshold
think trend drug price chang depend larg chang polici well elect
dont see near-term growth opportun biotech product
histor averag sales/trx monitor biotech product show shift
price growth sale driver
trump administr lawmak activ suggest chang feder drug
program though partisan gridlock impeach proceed limit implement
hh final rule requir manufactur disclos wac price televis ad feder judg rule hh
author mandat disclosur drug price summer
hh also withdrew propos rule would elimin drug rebat medicar medicaid plan
lawmak held recent public hear aim pbm payer drug manufactur though consensu appear exist
effect reduc drug price
current impeach proceed util time energi potenti would focus debat implement
propos chang drug program like intensifi signific partisan divid
executivecongressionalblueprint strategyactionactioninitiativepart dpart bmedicaidprivatex increas oversightxxxban pharmaci gag clausesxxxxpart patient tool provid inform oop costsxxdrug import initiativexxxxxbiosimilar action planxxxxxincreas gener approvalsxxxxxrem abus shame listxxxxxguid citizen petit anti-trust reviewxxxxximport sole sourc drugsxxxxxorphan drug design clarificationsxxxxxindication-bas managementxxstep edit medicar part bxxconsolid part d/b programsxxxintern price payment modelxxomb rule chang anti-kickback statutexxincreas formulari flexibilti protect classesx elimin drug rebat medicar medicaid plansxxxxcm dashboard increas price transparencyxxxxxend price reset line extensionsxx disclosur list price dtc advertisingxxxxxrep ipabxxxmedicar part donut hole changesxmedicarecr incent lower list pricesotherincreas competitionlow out-of-pocket costsstrengthen negoti biotech outlook ride momentum polit wind pick
state initi around price regul import transpar remain worth
number state also pursu legisl combat rise drug price subsequ litig surround
constitution approach import monitor
exampl popular type state initi includ requir price
transpar drug import program limit manufactur coupon offer pbm establish
volum purchas agreement multipl state
stateinitiativestatuscategorydescriptionalabamasb sign governorpbmsprohibit pbm restrict pharmaci disclos cost inform patient altern drugscaliforniaacr senat comm volum purchasingencourag governor engag nearbi state wish partner ca effort lower cost prescript drugscoloradosb governorimportationcal design program allow wholesal import prescript drug canada sale colorado consumersfloridahb governorimportationestablish wholesal canadian drug import programhb hous comm price transparencymanufactur must notifi state purchas health insur pbm gener assembl day advanc price increas period price increas must justifiedhb hous rule comm importationestablish wholesal canadian drug import program allow state licens wholesal import drugsmassachusettsh joint public comm importationestablish wholesal drug import programmichigansb senat comm importationestablish wholesal canadian drug import programminnesotasf senat comm importationestablish wholesal canadian drug import programmontanahb hous rule comm importationprohibit state offici law enforc offic imped inhibit import presecript drug person usenew hampshirehb hous comm couponsprohibit drug manufactur offer coupon discount cover insur copay deduct lower cost gener cover insur plannew yorkab senat comm importationcr wholesal prescript drug import program compli feder standard regulationsillinoi biotech outlook ride momentum polit wind pick
remain cheap balanc sheet strong larger
compani need growth pipelin diversif chang
narr slow ep growth pend patent cliff
record number cumul biopharma deal valu
announc public compani acquisit foster opportun
sustain momentum least earli half ahead
elect
celg-bmi agn-abbv deal highlight
appetit
time year larger
compani may play especi compani under-valued
and/or strateg crossroad
impli first
larg biopharma manag remain vocal desir pursu
deal larger scale well bolt-on could facilit
new team settl time solidifi
strategi
year acquir averag experienc increas share
price first day deal vs decreas last year
small/mid cap valuat escal substanti reduc
potenti return invest prospect acquir
though current wave like continu near term larger-
cap compani digest acquisit reset strategi could
see slowdown activ progress
bd activ could also wane elect approach potenti
increas uncertainti around monetari polici ftc stringenc
reimburs polici new administr
certain biopharma continu leverag cash primarili dividend
share buyback pose question industri overal
commit meaning
ftc take aggress stanc biopharma deal
signific delay complet merger
take balanc sheet strong money cheap pipelin thin better market recept see stage set
continu deal momentum record pace -- continu drive near-term upsid group -- though believ could
wane progress target digest potenti election-rel uncertainti
biopharma deal volum remain slightli last year high deal valu much
higher due celg-bmi announc
mid-year review number deal full year track inde saw
biopharma acquisit public biotech -- keep par pace
though actual deal valu ahead project deal valu though
heavili skew due bmy-celg merger
celg acquisit believ key take-away larg biopharma prefer smaller
earlier stage deal privat compani discount late-stag asset oppos larger
acquisit histor seen space baxalta/shir actelion/jnj pharmacyclics/abbv
said expect pace deal-mak continu increas pressur biopharma
compani could increas demand drive premium
acquisit gene therapi compani
note exclud takeda-shir deal graph base announc date
seen record number announc larger biopharma deal
number announc deal reach
total deal worth complet novemb announc notabl
ucb rarx achn await complet
notabl us-bas acquisit includ bmi acquisit celgen januari roch
acquisit februari acquisit array biopharma june
overal averag deal valu increas y-o-i though significantli influenc inclus
note exclud takeda-shir deal acquisit pacbio
select biopharma acquisit biotech
deal highli focus oncolog emerg gene cell therapi platform
expect see addit deal oncolog neurolog gene therapi
compani make biotech acquisit reward
averag
absolut share price chang basi acquir share appreci day sinc
acquisit announc vs share price reduct acquir day
referenc acquir share price chang factor macro dynam acquir slightli
under-perform broader market day deal announc wherea acquir
slightli outperform time frame
thirti day absolut chang acquir stock thirti day chang acquir stock price differ perform investor view like takeout candid
slow growth major patent cliff biopharma could help drive
mani larg cap compani gener disproportion share overal revenu hand
blockbust drug mani face impend patent cliff come year taf
meantim need make lost sourc revenu stimul growth may encourag futur
larg cap biotech predict show modest ep
cost capit increas
still remain rel cheap
note consensu estim obtain factset
saw slight decreas cash level larg cap biopharma cash deploy dividend
maintain y/i pace buyback consider reduc y/i
dividend steadili increas among biopharma share repurchas return histor rate
though consider lower level
said biopharma still flush cash biopharma may consid worthwhil use
capit alloc given limit valu gener share buyback
note cash recent report quarter dividend factset
total valuat among mid-cap recov oct-nov approach high seen april
biopharma manag continu sound rel bullish
companyrec sentiment think much busi usual cori clear capit alloc prioriti remain intact continu look way invest intern extern also grow dividend buy back share got activ bd effort area state strateg focu therapeut geograph maintain llyand like continu deal oncolog therapeut area interest includ immunolog also fair amount activ certainli transact earlier stage molecul immunolog open see right molecul also cours heavili invest diabet less sort biotech ventur capit activ natur fewer deal well continu area think come team come togeth continu evalu certainli area mention area look care complement intern expertis driven one therapeut area well continu evalu along dividend increas invest well opportunist acquisit make sens valu creation standpoint also realli good strateg fit expand agreement repres type target bd initi continu pursu help strengthen substrat next decadecompanyrec sentiment commentsbmyinvestor hc confer begin like focu primarili smaller earli scienc deal busi develop strategi remain critic long-term success compani central pillar capit alloc strategi expect us activ begin obvious larger deal first coupl year de-lever prioriti flexibl continu right scienc deal think go integr part strategi go forward mrkinvestor confer alway come back qualiti help merck creat greater valu go forward larg stuff made ton sens us look everyth els question find right asset fair price nvsinvestor call product fit well overal financi plan cours reason make acquisit stand-alone financi return strateg fit asset fit overal financi plan also great want stress immedi prioriti oper leverag restor good oper profit that go work hard time capit alloc prioriti unchang consid bolt-on acquisit immedi accret obvious strateg align biotech outlook ride momentum polit wind pick
feder trade commiss ftc take aggress stanc biopharma
though recent approv roche-onc deal reassur sign near term
saw heighten scrutini biopharma acquisit ftc relat anticompetit natur
hindranc innov
bristol-my squibb compani bm announc acquisit celgen equiti valu jan
ftc approv deal novemb condit divestitur otezla
ftc alleg bm acquisit could harm consum us market treatment moderate-
otezla sale valu
roch announc acquisit feb
us ftc uk competit market author took longer expect complet review
propos acquisit relat effect competit hemophilia market
tender offer deadlin extend time prior eventu deal closur mid-dec
spark hemophilia gene therapi asset potenti caus concern may
given roch excess market power hemophilia market given roch incent delay
ftc look current product merg entiti also consid pipelin product
might affect competit come year launch
ultim ftc approv acquisit posit sign continu view
least approach elect increas uncertainti around agenda potenti new
gene therapi new focu follow trend interest cellular therapi
past year
spark hemophilia genet blind
previous seen trend interest emerg biotechnolog cellular therapi compani
juno acquir celgen jan car-t cell therapi
kite pharma acquisit gilead aug car-t cell therapi
continu see co-develop deal continu big pharma compani also outright acquir
gene therapi cellular therapi compani
announc partnership gene therapi friedreich ataxia juli
expect interest gene therapi particularli aav base gene therapi pick
gene therapi technolog matur howev note payment model emerg technolog
still clear
platform manufactur capabl inher complex therefor command hefti
premium buyer
expect bring stephen hahn head fda
like serv
posit sector although scott gottlieb penchant drive
innov new product approv bring formal head fda
ned sharplesss interim leadership provid near-term
stabil agenc face number challeng mani
relat biotech addit hahn rel lack govern experi
may lead gener follow gottlieb footstep earli go
administr would good thing biotech
fda restructur appear gear toward streamlin help
modern process drug approv break subdivis
special unit ad addit admin function could
potenti reduc time market
development drug improv
transpar commun
effici drug approv continu strong demonstr earli
approv vrtx trikafta gbt oxbryta though read
gener competit well see net posit sector
new therapi particularli major unmet need could face fewer
barrier order reach market
fda shown flexibl toward novel mechan even face
adcomm skeptic willing consid addit data guid
increas number product approv quickli lead increas
competit though fda directli regul price drug
commission hahn seem align gottlieb encourag
competit innov allow drug come market market
forc self-regul price alreadi start increas
gener approv last sever year
increas competit
eventu also affect brand drug line
given scrutini recent year orphan drug design subsequ
revlimid unsurprisingli orphan drug design approv
start tick downward continu could limit
opportun subsequ develop advantag afford well
dissuad compani develop therapi diseas could
borderlin orphan base popul size
follow last year govern shutdown appear slow review
process number development drug polit climat appear
gotten polar elect grow closer anoth
govern shutdown could similar effect slow
development/approv timelin number late-stag asset
take believ overal regulatori trend continu look favor given appar continu push fda new treatment modal
innov chang fda appear gear toward streamlin drug assess approv process increasingli
polar polit environ combin appear somewhat unfavor trend approv volum temper bullish
expect regulatori landscap continu net tailwind sector
new fda commission stephen hahn influenc take shape follow scott
gottlieb departur ned sharplesss interim stay
dr hahn
oncolog
dr hahn train medic radiat oncolog work oncologist well work
nation cancer institut last year hahn heavili involv
oncolog research univers pennsylvania sinc md anderson cancer center
appoint chief medic execut hahn replac scott gottlieb formal
head fda seen leader favor overal landscap drug approv
ned sharpless serv interim commission gottlieb depart march note
time appear meaning chang gottlieb previous establish
earli know
dr hahn
shape fda
polici remain
tailwind
underway
visibl focal point hahn begin tenur directli relat
biotech note much focu confirm hear senat center effort
curb teenag vape e-cigarett regul oncologist hahn involv
plethora oncolog trial recent work focus tumor
microenviron checkpoint blockad radiolog interfer cancer indic us
would continu propon innov space hahn note would
work congress way lower drug price though provid limit specif said
would look propos polici specif whether individu polici effect without
regard polit hahn gener republican vs democrat support addit
hahn highlight support innov space indirect way combat rise
drug cost overal earli tell exactli hahn establish footprint fda
see rel limit government experi combin commit innov
endors gottlieb sign like radic departur current
fda approach practic
fda restructur underway goal modern optim streamlin drug review process
propos fda clinic pharm/tox structur
offic infecti
offic oncolog
offic
offic
offic cardio
heme endo
offic immuno
offic
offic specialti
divis anti-
divis
divis
divis
div cardiolog
div pediatr
divis
divis antivir
divis
divis
divis
medic genet
infecti
divis
divis
divis
divis
div hepatolog
neurosci
div pharm/tox
start initi reorgan fda new drug regulatori program creat offic specif area
expertis think could enabl better effici potenti faster standard regulatori process
could benefit earlier-stag compani regulatori road front enabl shorten lag time market vs
later-stag development and/or commerci competitor went old process could face potenti competit
number nme bla approv lowest sinc potenti limit
gov shutdown earli part year well on-going restructur
bla approv particular
slow vs
nme approv pick
vs
though appear modest
vs overal
declin total approv possibl
support idea
trend structur natur
vs indic chang fda
capit market estim compani report data decemb
approv nme new bla approvalsnm approv biotech outlook ride momentum polit wind pick
acceler approv larg line previou year remain rel rare
fda histor select
acceler approv
trend continu year
yield acceler approv line
sinc
acceler approv grant
indic poor prognosi
treatment rare diseas saw
acceler approv cancer
mm solid tumor mantl cell
lymphoma other sickl cell
anemia dmd
capit market estim compani report data decemb
druggener nameindicationapprov datereview prioriti orphan statusapprox popul phasedatatri designkeytrudapembrolizumabmetastat orr pr patient random dose line mo pt random open-label studi dose test ocalivaobetichol line iiialp reduct pt placebo-control randomizedexondi exon placebo mep higher pt random placebo control pt open-label single-armrubracarucaparibr/r brca mut ovarian recist brca mut pt single-arm open labelimfinzidurvalumabadvanc bladder yrphase orr cr pt single-arm open-labelandexxacoagul factor xarevers factor xa inhibitor-rel yrphase decreas anti-factor xa activ placebo control studi amikacinnon-tubercul mycobacterium yrphase sputum convers refractori pt placebo-control randomizationxpovioselinexorlate-lin multipl yrphase orr penta-refractori patient single-arm studyvyondi exon iidystrophin increas normal baselin normal pt random placebo control pt open-label approv grantedacceler approv biotech outlook ride momentum polit wind pick
number breakthrough therapi design level btd approv
difficult
breakthrough therapi design per year approv appear
level slightli declin steadi climb sinc
all-tim high breakthrough drug
approv continu downward trend
capit market estim compani report data decemb
breakthrough drug approv breakthrough design grantedbreakthrough design request grant biotech outlook ride momentum polit wind pick
orphan drug design level approv declin impli fda work
backlog
number orphan drug design grant orphan drug
rel stabil orphan
drug design
follow drop-off
impli fda
work orphan drug
backlog process start
declin orphan drug
also like speak
fact fda address
backlog could potenti
stabil similar
pattern seen design
includ uniqu indic separ approv
capit market estim compani report data decemb
mani regulatori event highlight halftim report posit outcom
sever still pend
companydrugeventtimingnotesregndupixentpdufa crswnp sbla jun approv soliri nmosd pdufa june date selinexor penta-refractori mmjuli boston trial serv confirmatori adcomm meetingsep favor efficaci favor safetysrptgolodirsen potenti us approvaldec august subsequ approv appealicptocau nda file accept pdufa date march nda tripl combo approv month earlyregneyleapdufa eylea pre-fil nda file delay pend adjunct studyobsvnolasibansubmit program prior filingincypemigatinib nda submiss accept pdufa date may nda potenti acceler approv r/r expect feedback insomnia add decis file pdufa data schizophreniasep decemb nda submiss alk-cmet amplifi yet submit expect agili potenti bla file yet file expect ind yet submit expect ind file yet submit expect expect januari adcomm schizophreniajuli upcom notabl regulatori event
companydrugeventtimingnotesbiibaducanumabbla submiss treatment alzheim decis treatment triple-class refractori regulatori submiss approv decisionjan ted prioriti review vedotinpdufa bladder cancer fill mbc file actin file breast nda accept hereditari bla accept r/r mantl cell submiss treatment ema accept cystic anemia mdsapr oca nashapr date opicapon parkinson diseaseapr scalp psoriasi sndaapr mbc apr date risdiplam smamay date pemigatinib cholangiocarcinomamay date oca nash submiss formul biotech outlook ride momentum polit wind pick
continued/anticip launch newer product class like adc
luxturna splice modul risdiplam agent novel
mechan diseas target reblozyl xpovio oxbryta oca reflect
biotech abil maintain diversif organ growth via success
invest cutting-edg maintain enthusiasm innov
return biib aducanumab regener interest overal
alzheim neurodegen field initi clinic data
amgn mrtx kra asset especi encourag
consid target previous consid undrugg
increas preval new therapeut modal new
gener bi-specif antibodi
radioligand therapi rlt tcr-t allogen approach evolv
combin synergist modal io-tki bcma-gsi
bring focu next frontier medicin therefor new
attract growth opportun may
govern vc fund academ research compani creation
continu sustain
regulatori environ remain permiss enabl faster path
sacrif risk/benefit
requir maintain high barrier entri
number
innov remain earli stage
develop need test clinic corrobor
efficaci ensur adequ safeti mrna
enthusiasm potenti pioneer technolog still
higher stage risk could lead substanti downsid
setback
regulatori approv path creat risk problem
novel agent approv acceler basi ultim
demonstr confirmatori efficaci need remain market
could gener downsid innov also
neg read-through cutting-edg product gener particularli
complex
new modal gene therapi car-t like requir new
approach manufactur deliveri reimburs may
add clinic risk may also necessit time
system adjust get necessari infrastructur place addit
tend lower margin product
take innov within biotech core driver sector remain high level particularli current environ regulatori facilit
expect continu advanc scienc around -emerg area includ gene manipul neurolog target oncolog gener steadi
stream high-potenti pipelin program enthusiasm group assum manufactur deliveri reimburs keep pace
see continu focu commerci launch sever key product new
potenti launch sgen
therapi newer gener
biolog bispecif antibodi
develop solid tumor
hematolog malign
explor new target
safeti profil toxicity/sa
concern
class like ild
ocular toxic mirvetuximab
potenti approv launch
tone adcomm meet
label requir biopsi
willing payer reimburs
physician enthusiasm prescrib
regul amen surrog
price baselin gene-bas
treatment monitor follow-up
overal size market
look toward key clinical/regulatory/commerci catalyst particularli oncolog neurolog immunolog
inflamm potenti modul enthusiasm therapeut area broader sector
exel/bmi checkmat top-line
potenti launch gild/glpg filgotinib
cabonivo rcc
ra
kpti ph iii boston readout
xpovio combin earlier line mm
addit sunfish firefish data
ph iii read-out amgn/azn tslp
potenti approv launch
inhibitor tezepelumab
roche/ptct risdiplam sma
potenti readout redwood
shorelin rainforest
mdd
continu launch abbv rinvoq
gmab/sgen top-line
tisotumab vedotin metastatic/recurr
potenti launch lumateperon
ph iii data select studi
filgotinib uc
first clinic data mruss
bispecif t-cell engag aml
potenti fda adcomm biib
top-lin rhapsodi ph iii data regn
arcalyst recurr pericard
first clinic data gmab next-gen
snda file drp
proof-of-concept data amgn
top-line ph iii data apr
potenti approv launch nbix
opicapon parkinson
supplement eu approv decis
otezla behcet syndrom
early-stag novel therapeut modal refin exist class continu emerg
next-gen biolog
ai improv target optim lead select next-gen biolog drug develop
expand pipelin complex therapeut biolog bsab fc-fusion protein adc
target radio-ligand therapi adcc tri-specif complex antibodi engin
gmab hexabodi duo-hexabodi technolog etc
increas t-cell engag enthusiasm
target diseas
on-going improv car-t improv upon efficaci safeti conveni on/off switch
expand crsp collabor acquir exon advanc dmd gene edit program
mani parallel approach zinc-fing nucleas increas likelihood could see gene
approach becom mainstay form treatment assum manufactur safeti hurdl
prqr oligonucleotid pipelin target genet blind usher syndrom ii blind
year develop number viabl rna-target therapi reach market spinraza
precis medicin
combin i/o chemo target therapi area develop surround increas
excit initi suffer setback inci epacadostat nktr howev indic
implement may simpl initi thought
precis medicin approv loxo astella etc site-agnost label breast breast etc
appear increas traction expand new regulatori approach class
agio mtap program target vulner tumor metabol applic number solid
emerg trend industri on-going shift toward complex therapeut
shift toward complex biolog agent cellular therapi gene therapi
continu fuel innov space result
product higher barrier entri due level know-how complex need
manufactur develop
overal lack tradit patent risk seen small molecul simpler biolog
abil treat previous untreat diseas even cure instanc better
address area unmet need improv upon current treatment paradigm
light chang innov environ see number key hurdl worth watch
like underappreci
scarciti area like gene therapi especi problemat ensur strong
oper excel given high degre complex space
manufactur scalabl challeng transit clinic commerci stage
margin compress discuss earn growth section
could see key catalyst relat number innov plu
gild/glpg ph iii uc data filgotinib
split congress work togeth drug
ph iii boston readout xpovio
pdufa potenti launch oca
combin earlier line mm
continu launch gene therapi bmrn
roche/ptct detail part data
sunfish firefish
chang fda organ structur
potenti affect new on-going review
sgen/gmab top-line result pivot ph ii
roche/ptct risdiplam sma pdufa
studi cervic cancer
ph checkmat readout
potenti continu especi earli
cabonivo rcc
year
top-line ph iii data apr reactiv
sgen/astella enfortumab vedotin bladder
ph ii data
potenti cautiou investor sentiment
near elect
rainforest data
macro influenc dynam biotech ipo
pace
prqr top-line result ph i/ii studi qr-
usher syndrom ii
gmda top-line ph iii omidubicel data
expir roche/nv ip lucenti
close mrk/arql deal/ apto
target onc next-gen btki opportun
investor expect key sector catalyst mix
note investor evenli divid catalyst suggest live debat around name though heavili
expect vrtx succeed ph ii defici studi investor dont expect sale regn eylea
see meaning impact novarti beovu
likelihood larg acquisit highest quantiti diverg respons investor evenli split
expect make acquisit
eylea sale declin st estimate q/q declin current est follow approv novarti beovu brolucizumab cabonivo demonstr competit efficaci comparison io tki combo rcc checkmat demonstr improv stabil visual field scale ushersyndrom type ii patient ph i/ii stellar studyicptoca receiv fda approv nash on/befor march pdufa without languag label biopsi confirm nashgild announc acquisit tisotumab vedotin demonstr competit efficaci io therapi trial metastatic/recurr cervic cancerxlrn ph ii pulsar studi sotatercept pah show reduct pulmonari arterialpressur pap reduct right ventricular hypertrophi monthssrpt commerci grade microdystrophin manufactur establish pivot studi initi patent invalid ptab base mylan ipramgn -report efficaci kra inhibitor colorect cancer converg vs currenttrend favor show clinic meaning stat sig increas function level ph ii studi deficiencyinvestor select least like outcom catalystsleast likelymost likelyaverageleast likelymost like biotech outlook ride momentum polit wind pick
sever space multipl competitor seen
competit dynam play decreas market share and/or
discount accur price expect go forward
biosimilar competitor begun enter market key
biotech drug price almost line brand product first
 rituxan biosimilar price discount may limit near-
competit natur mani space oncolog rare genet
diseas favor allow larger compani enhanc competit
sever competit area duopoli hiv
gild/viiv tardiv dyskinesia nbix/teva hcv gild/abbv car-t
nvs/gild appear somewhat equilibrium price share
perhap reduc concern biopharma willing engag price
trump administr initi support gener biosimilar brand
competit hit sever roadblock on-going impeach proceed
divert attent
competit dynam begin intensifi
sever
anti-vegf space inflammatori
diseas ra
though implement limit far increas competit drug
lawmak mani
administr
market key initi
competitor import market
necess signific
discount maintain market share increas lead reduc revenu
limit growth compet compani
target oncolog rare genet diseas direct competit may
less flip side rel small number patient specif
mutat desir age geograph locat etc rate-
limit clinic trial potenti slow pace clinic develop
sever high profil product current grow revenu expect
level begin declin come year due intensifi competit
though street est revis downward out-year project
still well consensu key drug spinraza dupix
take expect competit biotech remain brisk though note sever competit situat larg play
 cgrp lead revis out-year expect look ahead begin see
competit dynam play area like anti-vegf oral jak inflammatori diseas sma though slightli less
bearish view go vs still believ competit import headwind watch close
sever key drug class experienc intensifi brand competit
headwind biotech increas competit recently-approv establish brand drug
biib spinraza begun experi competit nvs/avxss zolgensma gene
therapi fda approv may although gene therapi
setback fda data manipul scandal clinic hold type zolgensma revenu
meaning beat con look potenti launch ptct/roch
oral risdiplam pdufa may addit sourc competit
nvss recent beovu approv launch kol feedback suggest
regn eylea wamd patient could switch beovu pend real-world experi
believ commerci risk could meaning impact sale
eylea experienc increas competit off-label brand avastin though
mitig somewhat recent avastin drug shortag
abbv rinvoq recent launch filgotinib await regulatori decis ra
usag dynam rinvoq humira potenti filgotinib vs rinvoq
import monitor
note continu competit area lymphoma mm car-t
bispecif antibodi gsk manufactur
import competit dynam evolv addit data readout potenti
competit amgn repatha regn praluent led price
agent reduc attempt gain share revenu agent miss
street est note recent acquisit mdco nv
highlight potenti sirna inhibitor inclisiran regulatori file
plan indic potenti addit competit space
potenti signific impact
current develop biosimilar remicad rituxan avastin herceptin humira
neulasta biosimilar competit increas though street est come recent
reflect
rituxan royalti could experi eros biosimilar competit first
biosimilar recent launch though next-gen ocrevu sale increas help partial fill
mani politician point increas approv avail biosimilar way reduc drug cost
gener propos increas avail
system payer could increasingli implement polici promot biosimilar substitut
exampl kaiser permanent one largest not-for-profit health plan
replac herceptin avastin biosimilar formulari report util
biosimilar drug
summari potenti underappreci disrupt forc across key therapeut class
discuss detail updat report game changer disrupt forc biotech
companyfranchis riskcompetitorspotenti disrupt xachiev risk factorbiibspinraza sma risdiplam tecfidera generic f/taf generic truvada biosimilar ofatumumab cartnon-car-t io cartliso-cel inject gsk/viiv oral hiv cocktail gsk/viiv tardiv dyskinesiacompet inhibitor teva agent neurodegen psychosi azn sunovion nrtti gene therapymini-dystrophin gene therapi gene therapymicrodystrophin gene therapi agent novo/gild azn fibrosiscftr mrna therapi approach aciu etc potenti ip threat viiv hh carthomebrew cartallogen off-the-shelf fibrosiscftr gene edit dmd therapyoligo-ab conjug dmd nippon cure approach sni excis gene therapyvrtx/exon srpt/duke novel tardiv dyskinesianext-gen antiphsychot scholar fibrosiscftr modul pti tech outlook ride momentum polit wind pick
out-year street estim key product recent reduc may need
revis light emerg competit
long-term street estim key flagship product revis downward sinc earli
close match est believ reduct like increas recognit
long-term street revenu expect like
although previou lofti expect dupix
fulli account entranc multipl
competitor like roche/ptct risdiplam gene
appropri come like room
still downward revis esp out-
year given intensifi competit
novel antibodi target tslp oral
earn growth
abil execut commerci keep expect check
sever large-cap compani demonstr abil revit
stori score major win defend crown
jewel revenu gener enbrel ad late-stag risk-fre growth
top-lin otezla regn multipl rebound fear near-
term competit beovu dwindl follow approv octob
large-cap biotech multipl remain discount rel pharma
one assum compani continu deploy capit
 bd improv out-year growth align
broader market larg cap overal would appear attract valu
small/mid cap product adopt gener beaten expect
gwph confirm smaller compani hold
launch like reduc typic street tendenc sell
launch
base buysid survey result investor see core franchis like
vrtx cf product gild hiv franchis regn eylea
street ep sale estim improv notic
second half suggest rise expect
could difficult exceed particularli top line
though long-term ep sale growth expect larger-
cap biotech market product rebound back half
remain near level start year near
lowest level year matur franchis pend patent cliff
higher revenu base like remain difficult large-cap
garner multipl histor
drug price increas leverag less serv catalyst
growth like continu
think street may underappreci key competit launch
space select jak vegf competit evolv sma
take come year believ import sector build upon progress includ solid
commerci execut bd help revit large-cap stori continu expand multipl closer larger pharma despit increas
expect matur franchis still see large-cap valuat overli discount dynam long-term growth
prospect look promis mid-cap biotech
large-cap biotech price-to-earnings multipl final trend upward toward pharma multipl though
gap remain valuat remain well multipl
note large-cap biotech includ
earn -ntm mean pharma tech outlook ride momentum polit wind pick
near-term large-cap biotech ep estim gradual improv out-year ep
revenu project inflect sharpli upward
could reflect pessim around competit regn eylea generalist favor return
amgn top-lin enbrel otezla near term remain cautiou long-term effect increas
note consensu
investor view gild hiv franchis vrtx cf franchis like beat
regn dupix bmrn palynziq like miss
vrtx cf franchis regn dupix nbix ingrezza drove debat
popular option beat miss revenu
palynziq enfortumab vedotin reblozyl sale spinraza nuplazid cf franchis hiv franchis select least like revenu beatsmost like miss es like averageleast likelymost like survey investor vs view potenti beat miss key product
consensu estim obtain factset
see growth return top-line remain cautiou expens vs street
continu see ep revenu growth slightli lag consensu estim onward
recent margin compress stabil
number driver make us anticip out-year margin stabil follow recent compress
remain worth watch sector due
shift toward complex product like car-t gene therapi higher cog vs
histor small molecul antibodi
higher oper expens associ buildout commerci manufactur infrastructur new
increas use partnership strategi royalti could also weigh margins/growth
averag return biotech ipo substanti higher past
year public investor appetit new issuanc could
compani go public earlier stage could compromis
post-ipo perform given greater risk clinic readout string
setback newli public compani could diminish ipo window
stabl averag capit rais per transact follow-on market
encourag expect capit rais
compani move later-stag develop
increas access privat capit sustain vc-fund privat
biotech continu creat robust pipelin potenti futur
capit need remain high among biotech estim
compani need rais capit may
suffici cash end year recess
concern emerg could substanti neg effect
decreas trend particip vc privat placement could
slow incub emerg start-up biotech compani
take improv post-ipo perform stabl follow-on market maintain healthi access capit biotech compani
see major financ hurdl public privat sector least first part howev potenti
neg data new early-stag compani emerg recess fear context increasingli high capit need
potenti diminish financ environ
ipo activ decreas averag rais saw slight increas
activ year ipo number ipo decreas averag rais per ipo
slightli higher previou year
post-ipo perform ipo outperform biotech ipo
averag total return offer price increas larg ipo
note price
total return biotech ipo offer price biotech ipo gross number rais per biotech outlook ride momentum polit wind pick
ipo market continu focu oncolog well foster innov neurolog larg
cancer remain main therapeut area invest interest repres biotech ipo
higher number vs relat immuno-oncolog signifi remain substanti
develop work done space newli public target cancer compani perform
neurolog anoth major theme within ipo market offer post-ipo return
larg market potenti
note price
therapeut areanumb iposaverag return offer surfac biotech outlook ride momentum polit wind pick
though averag biotech ipo perform post-ipo return vari
reflect substanti public market reward success also punish setback
karuna focus develop therapi util muscarin cholinerg receptor
treat psychosi cognit impair numer central nervou system disord saw largest
share appreci offer price
anchiano ancn focus develop small-molecul inhibitor ra wnt pathway
cancer therapi saw largest share depreci offer price
note price
biotech ipo perform offer price biotech outlook ride momentum polit wind pick
overal invest decreas though follow-on remain main financ channel
despit strong ipo market seen decreas biotech capit invest compar last year
follow-on continu major sourc financ biotech sector make capit
invest increas last year
proport vc privat placement decreas last year could reflect caution among
investor early-stag compani earn return large-cap public compani
note price
capit rais total biotech capit investmentiposfollow-onspriv biotech capit investmentiposfollow-onspriv placementvctot capit rais right axi total biotech capit invest capit rais right biotech outlook ride momentum polit wind pick
follow-on continu import sourc capit though given number biotech
requir cash recess concern close capit window could
overal follow-on total amount rais decreas past year though averag capit rais per follow-
remain gener unchang perhap reflect higher select investor
compani move later stage anticip potenti increas capit need
assum cash burn remain run-rat compani maintain balanc sheet least
month cash hand estim public biotech need rais capit
number could higher compani burn rate increas come year
though dramat dissimilar prior year signal recess
access capit diminish compani less robust balanc sheet could suscept
estim public biotech compani would suffici cash
note price
gross proce follow-on biotech outlook ride momentum polit wind pick
implic brexit biotech
uk brexit caus degre uncertainti european medicin agenc
rebas london amsterdam academ research fund state flux given difficulti
associ pan-european fund
gener elect decemb muddi water
howev privat fund environ remain strong us remain destin choic
europ limited/cm global research analysi impact recent bori johnson
victori brexit develop numer sector includ smid healthcar
mani resourc strategi
extend life cycl key product key detail remain scant
mani key patent expiri think specif may
emerg come year decis biib tecfidera ip
challeng combo/formul strategi inci jakafi
dispos
increas comfort
large-cap compani
franchis suscept patent expiri may abl
mitig bolt-on product settlement
litig win pipelin emerg
number favor procedur chang ipr process
director patent offic posit patent owner
fda implement number initi improv
speed biosimilar gener reach market uptak
rel slow
ip headlin like sever major product within large-
cap biotech biib tecfidera gild biktarvi yescarta
could headwind develop
greater regulatori anti-trust scrutini enabl faster pathway
backlog anda could continu cap potenti
longev
politician increasingli weigh drug-rel ip creat
implement
though potenti
shorter exclus period low view
signific
take biotech compani reason good job stave patent cliff concern litig victori pipelin enhanc
busi develop administr polici remain favor drugmak -- lawmak slow implement actual chang
favor uspto polici continu help brand drugmak defend ip flip side sever import life cycl strategi among mid/large-
cap compani need elucid eros biosimilar becom tangibl could headlin risk politician
increasingli weigh drug-rel ip
mani legaci product large-cap biotech continu face patent cliff within next year
increas investor concern base busi franchis maintain off-set
biib tecfidera ptab decis challeng patent expect earli februari
shorter-than-expect patent term extens worsen potenti backstop lack clariti sustain ms
franchis life cycl manag strategi vumer approv degre franchis protect upon
tec generic unknown estimate
give take year ip front gener biosimilar eros hit top-
line gener take bite y-o-i base estimate sale sensipar sale
biosimilar hit neulasta anoth y-o-i base estimate sale amgn litig victori
vs sandoz enbrel ip major win link legal eagl note defend crown
jewel least patent expiri still loom near term less-impact franchis vectibix
nplate seen
inch closer potenti patent expir continu explor sr
formul variou combo strategi believ import get clariti around
gild hiv franchis taf go gener uncertainti remain around mainten
hiv market domin though life-cycle extens strategi long-act capsid inhibitor
look increasingli promis could see greater discuss around biktarvi ip risk viiv trial
approach though ultim believ outbound royalti would materi
regn eylea eylea potenti lose patent exclus biosimilar entrant lucenti
expect soon could start chip away eylea sale sooner ip would suggest
clvss rubraca street disagr valid polymorph patent high dosag strength tablet patent could
place patent expir
exel cabometyx com patent solid eu patent includ
salt/polymorph expir like face invalid challeng possibl gener competit
earlier
disclaim report intend legal advic guarante accur inform purpos establish attorney-cli relationship
patent cliff mind believ made progress year wherea
still face signific hurdl
/- settlement potenti
approv vumer
advanc novel ms
potenti ofa launch rrm
posit filgotinib descovi prep
descovi prep approv rx inflect
generic truvada launch
glpg deal
victori vs sandoz enbrel ip case
expand indic footprint
expans eylea dose
clinic oral antagonist
advanc ruxolitinib sr
formul combo busi
advanc lucitanib fap
disclaim report intend legal advic guarante accur inform purpos establish attorney-cli relationship
still see multipl strategi large-cap biotech implement litig optim
diversifi medium term
ip regulatori
bpcia anda litig settlement
novel formul less frequent
conveni dose
citizen petit rem
new mode administr
clinic approv hurdl
next-gen product improv efficaci
supplementari ip dose regimen
strateg divestitur diversif
payer agreement reimburs
disclaim report intend legal advic guarante accur inform purpos establish attorney-cli relationship
intellectu properti consider broader biotech/pharma continu dynam
uspto director recent announc number procedur changes/propos relat ipr
regard claim construct standard new amend procedur simplifi requir
chang wont like appli retroact on-going ipr like biib believ longer-
term yield favor result brand drug manufactur defend patent
gener compani
part propos -mexico-canada agreement usmca provis reduc biolog
drug exclus current less back mani democrat wall
street journal report trump administr consid reduc period ip protect
biolog boost chanc usmca pass
recent guardian report senat berni sander alexandria ocasio-cortez sent
letter patent trademark offic call trump administr block gild
effort extend patent protect descovi
senat warren announc propos use govern author allow multipl compani
beyond innov produc patent drug effort reduc drug price elect
disclaim report intend legal advic guarante accur inform purpos establish attorney-cli relationship
new manag team across larger-cap biotech settl
go enabl elabor overal
strategi busi capit deploy
sever team remain incomplet untest
investor may set high bar success entrust
capit
high number execut come larg pharma bring
diversif ip reimburs challeng face matur
matur space enabl second act success execut
join take expertis smaller compani also help attract
investor interest capit influx given credibl provid
turnov mani mid/smid-cap biotech remain low enabl stabil
within high-growth potenti stori primarili guid scienc
growth space enabl groom numer
role remain
substanti scarciti talent experienc individu cutting-
edg area like gene therapi could increas personnel cost
underappreci headwind develop timelin
oper
sometim consider manag premium place early-
stage non de-risk compani well-regard leadership could
make valuat fragil exagger potenti downsid
compani peer experi setback
take re-establish senior manag team mani larger biotech enabl firmer articul busi strategi
proactiv capit alloc effort well receiv coupl lengthi tenur mid/smid-cap compani improv
percept stabil biotech space though sever team remain incomplete/untest scarciti valu oper personnel
cutting-edg scientif area could repres underappreci risk
get settl music chair time signific chang across larger-cap
biotech compani team fulli re-establish
old
new
head op jim meyer
head op anthoni hooper
head op murdo gordon
carmen bozic head clin devel
newer team perform commerci execut pipelin manag busi
develop test
experienc signific transit senior manag team almost complet
turn extern hire major focu capit deploy strategi
yet replac recently-depart evp central pipelin initi
stabil late execut posit
sever candid intern promot ceo cfo help ensur
smooth success plan reflect increas oper overlap among senior financ
 corpor develop role within matur compani
increas preponder personnel big pharma reflect increas need focu
challeng market access competit reimburs share larg pharma co
grow import manag complex organ shepherd bd small
corporate/busi develop effort longer adequ given high revenu base
build need veteran cfo bd leadership
oper commerci increasingli complex navig requir understand
remain less turnov smid/small-cap high-growth mid/larg cap compani mani
stabl senior manag year
second act legaci exec larger-cap acquir small-cap compani move
increasingli emerg privat public compani
exampl
leadershipnext endeavorjacki fous former celg presidentagiosandrew cheng former cmoakeroform alio executivesaligosform zs pharma executivesallakosform kite executivesallogeneform naurex executivesaptinyxscott smith former celg presid coobioatlajeff kindler former chairman ceocentrexiondoug william former head dcodiakalessandro riva former oncolog headglenmarkform recepto executivesgossamerform actelion executivesidorsianorbert bischofberg former cmokronosmik ehler former head dlimelightpaul friedman former presid ceomadrigaljeremi levin former teva ceoovidform idix executivestransl biogeorg scango former ceovir biotech outlook ride momentum polit wind pick
experienc leadership provid smaller compani veteran acumen stewardship
help foster investor confid expect downsiz trend continu
recent year seen mani legaci larger-cap acquir small/mid-cap
biotech senior execut move privat emerg compani includ spinoff
version prior compani leverag scientif clinic develop
trend expect like continu matur sector mani senior
leader success compani accomplish goal
financi wherewith take new challeng smaller start-up compani
ventur capit firm incub
instil much-need expertis early-stag compani often seen
provid strong valid platform portfolio attract investor interest
continu believ import balanc favor presenc well-
respect leadership risk substanti personnel premium rel extent de-
risk asset technolog leav open potenti magnifi downsid
companydrugeventtimingakbavadadustatcomplet enrol ph iii correct convers trial mirasol trial schizophreniadecemb fill mcrpc label expans file r/r dlbcl nda potenti acceler approv refractori potenti condit approv refractori approvaljanuari data form ph ii eclips trial releas ph ii atla trial mrk/arq fill mbc file actin file eu west virginia district court casefebruari ipr decis duefebruari delawar district court trial challeng patentmarch nda checkmat top-line andromeda al amyloidosi top-lin ted prioriti review march toledo initi ph stellar trial usher syndrom type dystrophin studi potenti nda part data present sunfish sma meet francefebruari data part firefish type sma ph iii treatment-nav acut gvhd result ph iii uti data ph iii boston studi svd decis tripl class refractori ph ii rocket studi fragil soticlistat data open-label arcad defici disord pulsar studi pah pulmonari arteri part studi potenti catalyst calendar continu
companydrugeventtimingakbavadadustattoplin result ph iii correct convers trial snda scalp psoriasisapril ph ii intrepid studi data uc select abphas ii primari adcomm nashapril fda decis bla r/r dlbcl target pdufa uterin bial pdufa parkinson diseaseapril data ph iii primros trial mbc april mecarbiltoplin data ph iii galactic-hf data ph iii trial ph b-cell cancer initi ph mono/combo conditional/registr trial b-cell ph poc studi paroxysm nocturn hemoglobinuria data phase ii data metastat melanoma eu data combin vedotin tv top-line result studi tv metastatic/recurr cervic result ph iii high-risk hematolog immunogen safeti data kidney transplant ruxolitinibdata ph iii true-ad trial safeti potenti activ aml patient dose escal decis abicipar wet approv trigger mileston payment file type result ph ii trial metastat basal cell result ph iii trial platinum-refractori cervic studi commerci eu regulatori result ph iii correct convers trial rrm seastar initi progress data prostar studi ph iii studi system ph iib studi formul et trial data ph iii trial eosinophil rsvp ph iib adult outpati rsv data ph iia trial potenti catalyst calendar continu
data data initi data rubraca opdivo combo updat aml bpdcn like reveal ph iii cin ph i/ii result tumor monotherapi data harbor solid tumor gbsphase ii interim meet fda mbc cervic top-line result phase studi sepofarsen data ph iii children asthma voyag trial children uncontrol perisst function data placebo-control studi biopsi data confirm studi beyond studi non transfus depend beta approv enrol complet egg data ph iii navig trial sever uncontrol data ph iii trial oral steroid depend data ph iii path-hom trial sever data ph ii captiv trial gastrointestin data ph iii md data parkinson data valrox hemophilia data ph ib/iia nash /eu approv launch data preliminari efficaci data preemptiv treatment data pi-combo imid combo trial multipl regulatori meet fda soticlistat data placebo-control elektra dravet syndrom lennox-gastaut syndrom result ph iii rhapsodi trial recurr data ph ii advanc trial schizophrenia-n start second file data ph i/ii trial nsclc data ph ii advis trial initi clinic data multi-cent ph combo studi chronic ph iii studi snda file chronic data ph iii trial osteoarthr data ph iii trial w/ cemiplimab ipilimumab chemo vs pembro high data ph ii trial w/ cemiplimab ipilimumab file long-term retreatment/safeti shorelin studi psg rainforest studi mdd comorbid insomnia data program peopl two biotech outlook ride momentum polit wind pick
